Medical research and health policy are increasingly focusing on the early detection of vascular diseases. New laws, AI-assisted diagnostics, and innovative care models aim to reduce mortality from heart and vascular diseases.
France Takes Action
On July 20, 2026, the French Parliament unanimously passed a law to combat cardiovascular diseases preventively. The measures include systematic screenings during check-ups, starting as early as six years of age for hypercholesterolemia.
Furthermore, pharmacists and physiotherapists are now allowed to conduct blood pressure measurements in primary care. The goal is to reduce the approximately 140,000 annual deaths in France due to these conditions.
The United States is also making strides. The updated US guidelines on dyslipidemia introduce specific target values for LDL cholesterol, bringing the country closer to European standards.
Experts emphasize that lowering LDL levels to below 100 mg/dl (under 70 mg/dl for high-risk patients) and maintaining blood pressure below 130/80 mmHg could prevent up to 80% of strokes.
AI in Cardiology: Promising Yet Limited
Three studies from 2026 illustrate the potential of artificial intelligence in heart medicine:
- CardiOmicScore: Analyzes blood samples to predict the risk of six different cardiovascular diseases up to 15 years before symptoms appear.
- ECG2Stroke: Assesses the stroke risk based on a ten-second ECG.
- QCG-Critical and ECG Buddy: South Korean systems achieve high accuracy (AUC 0.909) in predicting the 30-day mortality risk following surgeries.
However, caution is warranted. A benchmark test (RadLE 2.0) conducted on July 19, 2026, revealed the limitations: Experienced radiologists achieved 83% diagnostic accuracy, while leading AI models in radiology reached only around 30%.
Digital Health Checks for Insured Patients
In Germany, health insurance companies are adopting digital self-assessment tools. Since July 20, 2026, SBK and BIG direct health have offered their insured individuals a free, certified health check.
The tool “XUND” assesses lifestyle factors, family history, and pre-existing conditions, leading to individualized risk profiles for heart health and the musculoskeletal system.
Healthcare reality, however, reveals regional disparities. An analysis by the Federal Institute for Population Research (mortality data from 2002 to 2019) shows that the rate of medically preventable deaths in Rhineland-Palatinate is higher than in neighboring French regions, primarily due to coronary artery disease.
Socioeconomic factors, a looming shortage of healthcare providers, and the observation that women’s health complaints are statistically often taken less seriously are limiting aspects.
Therapy Optimization: The Right Medication Makes a Difference
A meta-analysis published in the JAMA journal (716 studies, involving over 150,000 participants) examined dropout rates associated with antihypertensive medications. The outcome revealed that sartans (angiotensin II receptor antagonists) possess the lowest dropout risk.
Conversely, calcium channel blockers and the combination of beta-blockers and thiazides exhibited significantly higher dropout rates. The authors emphasize that a patient-specific selection of active ingredients is crucial for long-term treatment success.
On July 21, 2026, the Joint Federal Committee (G-BA) commissioned two new experimental studies focusing on optimizing post-myocardial infarction treatments. Earlier on July 17, 2026, results from projects like “ReduRisk” and “REVASK” were approved. These aim to identify high-risk patients better in clinical practice and implement guidelines for chronic coronary heart disease treatment more consistently.
Disclaimer: No investment advice or buy/sell recommendations; market data may change without notice and carry significant loss risks. Our articles are generated and reviewed partially through AI assistance.
